Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announced that it intends to complete, subject to regulatory approval, a non-brokered private placement for gross proceeds of up to C$2,000,000 (the “Offering“). Negev Capital, a leading venture fund in the psychedelic drug development space, will lead the Offering….
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers – Pharmaceutical Technology
20mg/ml injections of Bizengri will be available to patients in coming weeks. Credit: aslysun / Shutterstock. Merus’ Bizengri (zenocutuzumab-zbco) has received accelerated approval from the
December 7, 2024